March 16, 2020 / 12:48 PM / in 24 days

BRIEF-Aerpio Pharmaceuticals Reports Q4 Loss Per Share Of $0.11

March 16 (Reuters) - Aerpio Pharmaceuticals Inc:

* AERPIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* Q4 LOSS PER SHARE $0.11

* AERPIO PHARMACEUTICALS- TO ADVANCE AKB-9778 TOPICAL FORMULATION INTO PHASE 2 TRIAL IN OPEN ANGLE GLAUCOMA WITH TOP LINE RESULTS EXPECTED IN Q1 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below